Document Detail

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
MedLine Citation:
PMID:  20008645     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To estimate the rate of pathologic complete response (pCR) to neoadjuvant chemotherapy in BRCA1 mutation carriers according to chemotherapy regimen.
PATIENTS AND METHODS: From a registry of 6,903 patients, we identified 102 women who carried a BRCA1 founder mutation and who had been treated for breast cancer with neoadjuvant chemotherapy. Pathologic complete response was evaluated using standard criteria.
RESULTS: Twenty-four (24%) of the 102 BRCA1 mutation carriers experienced a pCR. The response rate varied widely with treatment: a pCR was observed in one (7%) of 14 women treated with cyclophosphamide, methotrexate, and fluorouracil (CMF); in two (8%) of 25 women treated with doxorubicin and docetaxel (AT); in 11 (22%) of 51 women treated with doxorubicin and cyclophosphamide (AC) or fluorouracil, doxorubicin, and cyclophosphamide (FAC), and in 10 (83%) of 12 women treated with cisplatin.
CONCLUSION: A low rate of pCR was observed in women with breast cancer and a BRCA1 mutation who were treated with AT or CMF. A high rate of pCR was seen after treatment with cisplatin. An intermediate rate of PCR was associated with AC or FAC. The relative benefits of AC and platinum therapy need to be confirmed through follow-up of this and other cohorts.
Tomasz Byrski; Jacek Gronwald; Tomasz Huzarski; Ewa Grzybowska; Magdalena Budryk; Malgorzata Stawicka; Tomasz Mierzwa; Marek Szwiec; Rafal Wisniowski; Monika Siolek; Rebecca Dent; Jan Lubinski; Steven Narod
Related Documents :
10534295 - Cosmetic and postmastectomy breast implants: finnish women's experiences.
20467755 - Segmental measurement of breast cancer-related arm lymphoedema using perometry and bioi...
21314645 - Histamine-2 receptor antagonist use and incident dementia in an older cohort.
2913325 - Calorie-providing nutrients and risk of breast cancer.
24095245 - Tobacco, alcohol and cannabis use during pregnancy: clustering of risks.
20852945 - What i wish i'd known before surgery: brca carriers' perspectives after bilateral salip...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-12-14
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  28     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2010-01-18     Completed Date:  2010-02-04     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  375-9     Citation Subset:  IM    
Department of Genetics andPathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Antineoplastic Agents / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Breast Neoplasms / drug therapy*,  genetics
Cisplatin / administration & dosage
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Fluorouracil / administration & dosage
Genes, BRCA1
Methotrexate / administration & dosage
Middle Aged
Neoadjuvant Therapy
Taxoids / administration & dosage
Reg. No./Substance:
0/Antineoplastic Agents; 0/Taxoids; 15663-27-1/Cisplatin; 15H5577CQD/docetaxel; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 51-21-8/Fluorouracil; 59-05-2/Methotrexate
Comment In:
J Clin Oncol. 2010 Jan 20;28(3):361-3   [PMID:  20008634 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma.
Next Document:  Effects of Intensive Medical Therapy on Microemboli and Cardiovascular Risk in Asymptomatic Carotid ...